NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting
Clinical Trials
12 trialsNCT00106691 2023-06-12
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
GTx
Phase 3 Completed
NCT03351062 2017-11-22
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Chinese Anti-Cancer Association
Phase 3 Unknown
NCT02097459 2016-05-25
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT00044291 2015-07-31
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Completed
NCT02132390 2014-06-04
Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
Peking Union Medical College Hospital
Phase 3 Unknown
NCT00010322 2014-03-26
Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer
Intarcia Therapeutics
Phase 3 Terminated
NCT00129142 2013-11-15
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
GTx
Phase 3 Completed
NCT01214291 2013-11-15
TREAT2
GTx
Phase 3 Withdrawn
NCT00002529 2013-04-04
12-93
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT00267553 2007-09-10
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Terminated
NCT00097344 2007-08-23
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Terminated